A phase I dose escalation trial of MAGE-A3 and HPV-16 specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).
Dan P. Zandberg(University of Pittsburgh Medical Center), Martin J. Edelman(Fox Chase Cancer Center), Robert E. Morales(University of Maryland, Baltimore), Scott E. Strome(Northwestern Medicine Lake Forest Hospital), Ming Tan(University of Maryland, Baltimore), Sandra Rollins(University of Maryland, Baltimore), R. Taylor(University of Oxford), Ann B. Zimrin(University of Maryland, Baltimore), Jeffrey S. Wolf(University of Maryland, Baltimore), Dean L. Mann, Kevin J. Cullen(University of Maryland, Baltimore), Robert A. Ord(University of Maryland, Baltimore), Joshua E. Lubek(University of Maryland, Baltimore), Olga Goloubeva, John C. Papadimitriou(University of Maryland, Baltimore)
Cited by 4
Related Papers
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|5.1k
The Banff 97 working classification of renal allograft pathology
|Kidney International|1999|3.1k
Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions
|American Journal of Transplantation|2008|1.9k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k